OPK Stock - OPKO Health, Inc.
Unlock GoAI Insights for OPK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $713.14M | $863.50M | $1.00B | $1.77B | $1.44B |
| Gross Profit | $311.03M | $318.13M | $288.22M | $581.52M | $541.00M |
| Gross Margin | 43.6% | 36.8% | 28.7% | 32.8% | 37.7% |
| Operating Income | $-152,065,000 | $-157,021,000 | $-226,253,000 | $18.75M | $57.71M |
| Net Income | $-53,224,000 | $-188,863,000 | $-328,405,000 | $-30,143,000 | $30.59M |
| Net Margin | -7.5% | -21.9% | -32.7% | -1.7% | 2.1% |
| EPS | $-0.08 | $-0.25 | $-0.46 | $-0.05 | $0.05 |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 20th 2025 | JP Morgan | Initiation | Neutral | - |
| October 31st 2025 | Jefferies | Downgrade | Hold | $1.6 |
| April 25th 2025 | JP Morgan | Initiation | Neutral | - |
| June 29th 2023 | Barrington Research | Upgrade | Outperform | $2 |
| December 15th 2022 | H.C. Wainwright | Initiation | Buy | $3 |
Earnings History & Surprises
OPKEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.07 | — | — | — |
Q4 2025 | Oct 29, 2025 | $-0.02 | $0.03 | +250.0% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $-0.12 | $-0.19 | -58.3% | ✗ MISS |
Q2 2025 | Apr 30, 2025 | $-0.06 | $-0.10 | -66.7% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.08 | $0.01 | +112.5% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.10 | $0.03 | +130.0% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.09 | $-0.01 | +88.9% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.09 | $-0.12 | -33.3% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $-0.09 | $-0.09 | 0.0% | = MET |
Q4 2023 | Nov 6, 2023 | $-0.09 | $-0.11 | -22.2% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.07 | $-0.03 | +57.1% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.07 | $-0.02 | +71.4% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-0.11 | $-0.11 | 0.0% | = MET |
Q4 2022 | Nov 8, 2022 | $-0.10 | $-0.11 | -10.0% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.00 | $-0.04 | -1851.2% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.08 | $-0.08 | 0.0% | = MET |
Q1 2022 | Feb 24, 2022 | $-0.02 | $-0.11 | -450.0% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $0.02 | $0.04 | +100.0% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $-0.01 | $-0.03 | -155.5% | ✗ MISS |
Latest News
JP Morgan Initiates Coverage On OPKO Health with Neutral Rating
➖ NeutralJefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6
📉 NegativeBarrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target
📈 PositiveOPKO Health Q3 2025 Adj. EPS $(0.10) Misses $(0.04) Estimate, Sales $151.700M Miss $160.783M Estimate
📉 NegativeAn OPKO Health's Modex Therapeutics Company Doses First Patient In Its Phase 1/2a Trial Of MDX2004, A First-In-Class Trispecific Antibody-fusion Protein For Advanced Cancers
📈 PositiveFrequently Asked Questions about OPK
What is OPK's current stock price?
What is the analyst price target for OPK?
What sector is OPKO Health, Inc. in?
What is OPK's market cap?
Does OPK pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OPK for comparison